Hepatocellular Carcinoma New Indication: Adjuvant Atezolizumab – Bevacizumab in HCC Ulas D. Bayraktar, MD 2023-06-24
GastroEsophageal Cancer New Protocol: Trastuzumab, Ramucirumab, and PACLitaxel for her2-Positive Advanced Gastroesophageal Cancer Ulas D. Bayraktar, MD 2023-06-24
Non-Small Cell Lung Cancer New Reference: Encorafenib and Binimetinib in bRAF V600E Mutated NSCLC Ulas D. Bayraktar, MD 2023-06-24
Biliary Tract Cancer New Protocol: Tucatinib and Trastuzumab in her2-Positive Biliary Tract Cancer Ulas D. Bayraktar, MD 2023-06-24
Diffuse Large B Cell Lymphoma New Protocol: Rituximab, Lenalidomide, and Ibrutinib in DLBCL Ulas D. Bayraktar, MD 2023-06-14
Skin Cancer (Other than Melanoma) New Indication: Neoadjuvant Cemiplimab for Cutaneous Squamous Cell Cancer Ulas D. Bayraktar, MD 2023-06-14
Bladder Cancer New Indication: Durvalumab with CISplatin and Gemcitabine in Biliary Tract Cancers Ulas D. Bayraktar, MD 2023-06-14
